The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors

The efficacy and peripheral blood predictors in recurrent platinum-resistant ovarian cancer patients treated with immune checkpoint inhibitors

Abstract Introduction The prognostic factors associated with recurrent platinum-resistant ovarian cancer treated with immune checkpoint inhibitor (ICI) therapy need to be identified. Methods We retrospectively analyzed the efficacy of ICI therapy in patients with recurrent platinum-resistant ovarian...

Full description

Saved in:

Bibliographic Details
Main Authors:	Baoyue Pan, Xiaojing Zheng, Yongwen Huang, Wei Wei, Shije Xu, Siyu Chen, Jiaxin Yin, Yu Zhang, Jundong Li, Min Zheng
Format:	Article
Language:	English
Published:	BMC 2025-08-01
Series:	Journal of Ovarian Research
Subjects:	Immune checkpoint inhibitor Platinum-resistant ovarian cancer, peripheral blood cytokine
Online Access:	https://doi.org/10.1186/s13048-025-01755-7
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Efficacy of pembrolizumab in combination with bevacizumab and oral metronomic cyclophosphamide in the treatment of platinum resistant recurrent ovarian cancer: a retrospective observational study
by: Alexandra R. Steck, et al.
Published: (2025-08-01)

Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
by: Su H, et al.
Published: (2025-02-01)

Evaluation of platinum-free interval and chemotherapeutic effect of subsequent platinum-containing chemotherapy in patients with recurrent ovarian cancer initially treated with bevacizumab: SGSG018/Intergroup study
by: Tamaki Tanaka, et al.
Published: (2025-06-01)

The leadership of topotecan in the treatment of recurrent platinum-resistant ovarian cancer
by: K. E. Borisov
Published: (2014-07-01)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
by: Nicholas Cardillo, et al.
Published: (2022-10-01)

Preliminary study on the role and mechanism of ISG15 in exosomes in platinum resistance in ovarian cancer
by: TIAN Yanan, ZHENG Hui, YAN Tianqing, ZHANG Heng, LU Renquan, GUO Lin
Published: (2025-04-01)

Survival Analysis of Ovarian Carcinosarcomas Depending on Platinum or Doxorubicin Based Adjuvant Chemotherapy
by: İlker Selçuk, et al.
Published: (2015-04-01)

Deep learning based on ultrasound images to predict platinum resistance in patients with epithelial ovarian cancer
by: Chang Su, et al.
Published: (2025-05-01)

Recurrent ovarian cancer: prolongation of the platinum-free interval with the use of a weekly treatment regimen of hycamtin (topotecan)
by: E. G. Novikova, et al.
Published: (2014-07-01)

HELQ upregulates PARP1 to drive platinum resistance and predict therapeutic response in ovarian cancer
by: Shuran Tan, et al.
Published: (2025-07-01)

Long-term effect of pegylated liposomal doxorubicin in recurrent platinum-resistant ovarian cancer: а clinical case
by: I. A. Pokataev, et al.
Published: (2015-11-01)

Ojeok-san enhances platinum sensitivity in ovarian cancer by regulating adipocyte paracrine IGF1 secretion
by: Jiong Ma, et al.
Published: (2024-12-01)

Bevacizumab in Platinum-Sensitive Recurrent Epithelial Ovarian Cancer: A Risk-Stratified Analysis
by: İrem Öner, et al.
Published: (2025-06-01)

The Role of Initial Neutropenia and Neutrophil Dynamics in Personalizing Chemotherapy for Platinum-Resistant Ovarian Cancer
by: Radu-Dumitru Dragomir, et al.
Published: (2025-03-01)

Immune checkpoint blockers and ovarian cancer
by: Chinmoy K Bose
Published: (2017-01-01)

Do all patients that undergo a ‘complete’ secondary cytoreductive surgery for platinum-sensitive recurrent ovarian cancer, benefit from it?
by: Bhatt Aditi, et al.
Published: (2024-07-01)

THE VALUE OF CYTOREDUCTIVE SURGERY FOR ISOLATED LYMPH NODE RECURRENCE OF OVARIAN CANCER
by: H. I. Mamajonov, et al.
Published: (2020-07-01)

Mitotic MTH1 inhibitor karonudib kills epithelial ovarian cancer independent of platinum sensitivity
by: Rachel M. Hurley, et al.
Published: (2025-06-01)

CT-based radiomics model to predict platinum sensitivity in epithelial ovarian carcinoma: a multicentre study
by: Mengge He, et al.
Published: (2025-07-01)

Unveiling novel biomarkers for platinum chemoresistance in ovarian cancer
by: Wang Caixia, et al.
Published: (2025-01-01)

Ovarian cancer: new accents treatment of patients with platinum-sensitive relapses
by: A. G. Kedrova, et al.
Published: (2016-11-01)

CDK6 protects epithelial ovarian cancer from platinum‐induced death via FOXO3 regulation
by: Alessandra Dall'Acqua, et al.
Published: (2017-08-01)

Pembrolizumab combined with lenvatinib and metronomic cyclophosphamide in platinum-resistant ovarian cancer: a case report of durable clinical response
by: Guanlin Dai, et al.
Published: (2025-08-01)

Immunomodulatory effects of mononuclear 5,6-epoxy-5,6-dihydro-1,10-phenanthroline platinum(II) complex
by: Stanisavljević Isidora, et al.
Published: (2024-01-01)

Influence of initial platinum-based chemotherapy on levels of He-4 protein and VEGF-A in primary tumors and metastases from ovarian cancer
by: E. M. Frantsiyants, et al.
Published: (2022-01-01)

The expression of immunohistochemical biomarkers PAX8 and CD117 in platinum resistant ovarian cancer at Saiful Anwar General Hospital, Malang, Indonesia
by: Robby Rinaldi Widodo, et al.
Published: (2025-04-01)

Systemic Immune-Inflammation Index Predicts Outcomes in Platinum-Resistant Relapsed Ovarian Cancer
by: Luxitaa Goenka, et al.
Published: (2024-10-01)

Functional validation of somatic variability in TP53 and KRAS for prediction of platinum sensitivity and prognosis in epithelial ovarian carcinoma patients
by: Al Obeed Allah Mohammad, et al.
Published: (2025-12-01)

Research progress of immune checkpoint inhibitors in ovarian cancer
by: Lingli Zhao, et al.
Published: (2024-12-01)

Immunohistochemical parameters of serous ovarian carcinomas and possible mechanism of development of resistance to platinum-based drugs
by: G. V. Zhukova, et al.
Published: (2024-09-01)

Tumor Small Extracellular Vesicle‐Transmitted LncRNA CATED Promotes Platinum‐Resistance in High‐Grade Serous Ovarian Cancer
by: Yi Liu, et al.
Published: (2025-08-01)

The real-world safety profile of pemetrexed and platinum with or without pembrolizumab: insights from a comparative analysis of FAERS database
by: Shun Li, et al.
Published: (2025-04-01)

The Quantitative Indices of ERCC1 Expression in Serous Ovarian Cancer Tissue and the Efficacy of First-Line Platinum-Based Chemotherapy
by: T. A. Bogush, et al.
Published: (2020-05-01)

Integrating bulk RNA-seq and scRNA-seq analyses with machine learning to predict platinum response and prognosis in ovarian cancer
by: Tingting Gao, et al.
Published: (2025-05-01)

Machine learning for epithelial ovarian cancer platinum resistance recurrence identification using routine clinical data
by: Li-Rong Yang, et al.
Published: (2024-11-01)

Targeting the SPC25/RIOK1/MYH9 Axis to Overcome Tumor Stemness and Platinum Resistance in Epithelial Ovarian Cancer
by: Xingyu Jiang, et al.
Published: (2024-12-01)

RADIOTHERAPY IN MANAGEMENT OF BRCA-POSITIVE OVARIAN CANCER
by: T. V. Gorodnova, et al.
Published: (2017-09-01)

The trajectory of conditional, recurrence-free, and long-term survival in a complete 10-year cohort of patients with advanced ovarian cancer
by: Nina Groes Kofoed, et al.
Published: (2025-03-01)

Platinum/Platinum Sulfide on Sulfur-Doped Carbon Nanosheets with Multiple Interfaces toward High Hydrogen Evolution Activity
by: Mou Zhang, et al.
Published: (2024-09-01)

Experience of using chemotherapy treatment for the first recurrence of ovarian cancer
by: V. N. Zhurman
Published: (2025-01-01)